REG - RTW Biotech Opp. - Kailera Therapeutics announces Series B financing

RTW Biotech OpportunitiesAnnouncement

15/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251015:nRSO3551Da&default-theme=true

RNS Number : 3551D  RTW Biotech Opportunities Ltd  15 October 2025

LEI: 549300Q7EXQQH6KF7Z84

15 October 2025

RTW Biotech Opportunities Ltd

Kailera Therapeutics announces $600 million Series B financing

 

RTW Biotech Opportunities Ltd (the "Company" or "RTW Bio"), the London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, is pleased
to note the announcement by private portfolio company Kailera Therapeutics,
Inc. ("Kailera") on its $600 million Series B financing round.

 

Kailera is a clinical-stage biopharmaceutical company advancing a broad
pipeline of next-generation therapies for the treatment of obesity. Its lead
product candidate, KAI-9531 is a novel dual GLP-1/GIP receptor agonist
administered via once-weekly subcutaneous injection with potentially
best-in-category weight loss. As at 30 September, Kailera represented 4.0% of
RTW Bio's NAV. RTW Bio invested $7.4 million as part of the Series B financing
round, which represents a 1.4x step-up to the Series A financing round.

 

The Series B financing round was led by new investor Bain Capital Private
Equity. Additional new investors comprise leading mutual funds and investors,
including Adage Capital Management LP, Canada Pension Plan Investment Board
(CPP Investments), Invus, Janus Henderson Investors, Perseverance Capital,
Qatar Investment Authority (QIA), Royalty Pharma, Surveyor Capital (a Citadel
company), accounts advised by T. Rowe Price Associates, Inc., and an
undisclosed large mutual fund. Kailera's existing investors, Atlas Venture,
Bain Capital Life Sciences, RTW Investments, and Sirona Capital, also
participated in the round.

 

The financing will support the advancement of Kailera's leading obesity
portfolio, including a global Phase 3 clinical program of KAI-9531. The
financing will also advance KAI-7535, an oral small molecule GLP-1 receptor
agonist that demonstrated competitive weight loss in a Phase 2 clinical trial
in China, to global clinical trials. Kailera completed End-of-Phase 2 meetings
with the U.S. Food and Drug Administration and plans to initiate its global
Phase 3 program by year-end. Additionally, Kailera continues to progress its
earlier stage programs, KAI-4729, an injectable GLP-1/GIP/glucagon receptor
tri-agonist, and KAI-9531 formulated as a once-daily oral tablet. Beyond its
current pipeline, Kailera has certain rights to new formulations of licenced
products and rights of first refusal over selected assets in Hengrui's
metabolic disease portfolio

 

Rod Wong, CIO of RTW Investments, said, "Our further investment in Kailera
reflects our strong conviction in the obesity space, where we're seeing
growing momentum. Around 40% of RTW Bio's private portfolio exposure comprises
companies focused on next-generation obesity treatments and this financing
round demonstrates the strong interest in the space and value in our private
assets, especially when combined with the recently announced acquisition of
Metsera by Pfizer. Kailera's lead program, KAI-9531, is advancing into global
Phase 3 trials with data that suggest best-in-category potential. Combined
with a broad pipeline and strong execution, Kailera is positioned to be a key
player in the next wave of obesity innovation"

 

Kailera's announcement can be found here
(https://www.kailera.com/press-release/kailera-therapeutics-announces-600-million-series-b-financing-to-further-advance-pipeline-of-next-generation-therapies-for-the-treatment-of-obesity/)
.

 

Enquiries:

 RTW Investments, LP - Investment Manager  +44 (0)20 7959 6362

 Oliver Kenyon                             biotechopportunities@rtwfunds.com

 Woody Stileman

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                           +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)               +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker   +44 (0)20 7260 1000

 Freddie Barnfield

 Nathan Brown

 BofA Securities - Joint Corporate Broker  +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                  +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(http://www.rtwfunds.com/rtw-biotech-opportunities-ltd)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUEZLFFEBLXFBQ



            Copyright 2019 Regulatory News Service, all rights reserved